Grass pollen allergy immunotherapy - Bial

Drug Profile

Grass pollen allergy immunotherapy - Bial

Alternative Names: Allergovac depot Olea; Allergovac grass pollen; Allergovac grass pollen depot; Allergovac Poliplus; BIA 14-2964; Olea europaea extract - Bial

Latest Information Update: 15 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bial
  • Developer BIAL; ROXALL Medizin GmbH
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 15 Jun 2017 Bial completes a phase II trial for Allergic rhinoconjunctivitis (sensitised to Olea europaea) in Spain (SC) (EudraCT2014-001569-29)
  • 01 Jun 2016 Bial completes a phase I trial for Allergic rhinoconjunctivitis in Spain (SC) (NCT02849249)
  • 01 May 2016 Bial completes a phase II trial for Allergic rhinoconjunctivities (sensitised to Parietaria judaica) in Spain (EudraCT2014-001459-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top